KRAS Mutations Predict Inferior Post-Remission Outcomes in Newly Diagnosed Acute Myeloid Leukemia With MAPK Pathway Mutations.
A specific genetic mutation in blood cancer independently predicts worse outcomes, identifying a subgroup that may benefit from mutation-targeted drugs.
Retrospective analysis of 74 MAPK-mutated AML patients demonstrates KRAS mutations independently confer inferior post-remission OS (HR 2.14) and RFS compared to other MAPK pathway mutations, suggesting KRAS-mutated AML is a distinct high-risk subgroup. These findings, while limited by single-center retrospective design, support evaluation of KRAS-targeting approaches in AML and validation in larger multicenter cohorts.
What the study was
- Study design
- Retrospective single-center cohort study (n=74; logistic and Cox regression)
- Population
- Newly diagnosed MAPK-mutated AML patients at University of Iowa Health Care
- Sample size
- 74
- Category
- Genomics/Precision Medicine
- Maturity
- Exploratory
- Journal
- European journal of haematology
Why it surfaced
Largest focused KRAS-specific prognostic analysis in MAPK-mutated AML context (n=74). Single-center retrospective limits evidence, but KRAS-mutated AML is an emerging targetable subgroup with RAS inhibitors in development. Eur J Haematol.
A plain-language summary of published research — not medical advice. Talk to a clinician about your own care.